Madrigal Pharmaceuticals Reports Strong Q1 2026 Performance with Rezdiffra's Blockbuster Sales
Madrigal Pharmaceuticals reported that its drug, Rezdiffra, achieved over $1.1 billion in trailing 12-month net sales and is positioned as a foundational therapy for metabolic-associated steatohepatitis (MASH). The company attributes this success to an expanded U.S. market driven by increased diagnosis rates and broader prescriber adoption.
Topics: blockbuster drug performance earnings call summary pharmaceutical